Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.63 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR5A | P47898 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6964650 | 0.94 | ADRB1 (0.71) | ADRB1HTR7HTR6HTR3EHTR3B | |
| SCHEMBL9881483 | 0.88 | ADRB1 (0.46) | ADRB1HTR7HTR6CHRNB2CHRNA4 | |
| SCHEMBL5235956 | 0.88 | ADRB1 (0.63) | ADRB1HTR7HTR6CHRNB2CHRNA4 | |
| SCHEMBL5231793 | 0.85 | CHRNB2 (0.50) | ADRB1HTR7HTR6CHRNB2CHRNA4 | |
| SCHEMBL5231120 | 0.85 | ADRB1 (0.86) | ADRB1HTR7CHRNB2CHRNA4HTR3E | |
| SCHEMBL19998610 | 0.85 | HPGD (0.47) | ADRB1 | |
| SCHEMBL12583478 | 0.85 | ADRB1 (0.47) | ADRB1 | |
| SCHEMBL10151434 | 0.83 | HPGD (0.50) | ADRB1 | |
| SCHEMBL9881498 | 0.83 | HPGD (0.50) | ADRB1 | |
| SCHEMBL21533600 | 0.83 | ADRB1 (0.65) | ADRB1HTR7HTR6CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | ADRB1 241/4885HTR7 3237/4885HTR6 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.